Study probes whether tracking everyday chemical exposures could transform breast cancer prevention
NCT ID NCT07690852
First seen Jul 08, 2026 · Last updated Sep 01, 2026 · Updated 3 times
Summary
This study investigates whether adding environmental exposure risk assessments to standard care is useful and acceptable for women at average or high risk of breast cancer, as well as those diagnosed with early-onset breast cancer. Researchers will survey patients and providers about their attitudes, willingness, and preferences regarding such assessments. A subset of participants will also wear a wristband to measure chemical exposures. The goal is to understand how environmental factors might be integrated into personalized breast cancer prevention and care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could pave the way for integrating environmental exposure monitoring into routine breast cancer prevention and care.
- What could go wrong
- This is an observational study focused on attitudes and feasibility, not on directly preventing or treating cancer. Results may not change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 423 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Female patients aged 18 years or older who either are considered average risk for developing breast cancer or high-risk for developing breast cancer or have early-onset breast cancer as well as providers at City of Hope.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * AIM 1 INCLUSION CRITERIA: * ONE of the following: * Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no Pathogenic/Likely Pathogenic \[P/LP\] in breast cancer related genes) OR high risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model or gene mutation carrier, P/LP carrier in breast cancer related genes including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) OR early onset breast cancer (defined by a breast cancer diagnosis in a patient younger than 50 years of age) * Age: ≥ 18 years * Speak English or Spanish * Sex: female * Willingness to: * Participate in study activities * Permit medical record/ clinical laboratory result review * AIM 2 INCLUSION CRITERIA * Practice at COH (i.e., genetic counselors, geneticists, oncologists, nurse practitioners) * Willingness to: * Participate in study activities * AIM 3 INCLUSION CRITERIA: * Provide written consent * ONE of the following: * Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no P/LP in breast cancer related genes) OR High risk: empirical risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model and no P/LP in breast cancer related genes) OR High Risk: gene carrier (defined by P/LP carrier in breast cancer related genes, including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) * Age: ≥ 18 years * Speak English or Spanish * Sex: female * Willingness to: * Wear the wristband for 1 week * Participate in study activities * Permit medical record/ clinical laboratory result review
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Green dye vs blue dye: which finds Cancer-Linked lymph nodes better?
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- Can exercise and nutrition prehab help breast cancer patients through chemo?
- Can a clotting drug cut mastectomy wound drainage?
- A simple dye might replace radioactive tracers in cancer staging
- Can new tracers make many cancers light up on scans?